Sandy Gardiner

Sandy Gardiner

Sandy Gardiner joined FLG in 2023 with 30+ years of experience as an EVP and CFO at private and public companies in the Life Sciences sector. She has held CFO roles in both domestic and global companies, operating as a director to international subsidiaries throughout Europe, Asia Pacific and Latin America. Her tenures include leadership positions at development-stage, pre-commercial to enterprise, commercial $350M+ biotech and medtech companies. Sandy has been involved in executing numerous financial transactions, including IPOs, secondary offerings, private placements, reverse mergers, rights offerings, ATMs and debt facilities. She has raised over $1Bn in capital and completed two M&A transactions.

Prior to joining FLG, Sandy served as the Chief Financial Officer, Executive Vice President of Finance and Administration and Treasurer of Pulse Biosciences, Inc., a publicly traded medtech company (2019-2022).  Sandy also served as the Secretary of Pulse Biosciences from November 2019 until October 2021. She successfully led Pulse Biosciences through its preparation for commercialization in the U.S., EU and Canada, building global infrastructure and establishing an international subsidiary and direct sales force while growing its market cap to $1B+. She also completed two oversubscribed Rights Offerings while at Pulse, a $50M PIPE, $60M ATM and $250M shelf registration.

Before Pulse, Sandy was Executive Vice President and Chief Financial Officer at Cutera, Inc. (2017-2019), a publicly traded global aesthetic company where she was instrumental in initiatives to increase efficiencies for long-term growth and scaling. As CFO, Sandy was part of the management team responsible for launching the company’s first consumable revenue product, ultimately growing to 25% of the company’s revenue base. As part of this effort, she helped implement a new S&OP process integrating Sales, Marketing, Production and Finance, strengthened gross margins and internal financial controls and implemented ASC 606 to meet GAAP requirements.

Sandy has also served as Vice President, Finance, Chief Financial Officer and Corporate Secretary of Tria Beauty, Inc. (2015-2017), a venture-backed manufacturer of aesthetic laser medical devices. Her role was instrumental in building the foundation for the company’s successful sale in 2017 by reducing operating losses, increasing EBITDA and de-levering the capital structure to attract new investors, closing a $25M PIPE and reducing debt.

Prior to Tria Beauty, Sandy held CFO positions at Aptus Endosystems, Inc., a VC-backed medical device company targeting endovascular aneurysm repair, at Ventus Medical, Inc., a manufacturer of sleep apnea devices, at Vermillion, Inc., a publicly traded ovarian cancer diagnostic company, and at Lipid Sciences, Inc., a public biotech company targeting HDL therapies. Earlier in her career, Sandy held management positions of increasing responsibility at Cardima, Inc., Comac, Inc. and Advanced Cardiovascular Systems, Inc.

Sandy currently serves as board director of LevitasBio and board chair of the Valley Humane Society. Sandy previously served on the board of directors of Bend Research, Inc. and Lucira Health, Inc. including serving as Audit Committee Chair and as a member of the Nominating and Corporate Governance Committee.

Sandy received her Bachelor of Arts in Management Economics from the University of California at Davis.